네오이뮨텍

950220KOSDAQ자연과학 및 공학 연구개발업

61.3 / 100

Reference Date: 2026-06-10

Financial Score20.5 / 40

News Sentiment17.8 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Surged 24.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neoimmune Tech is a biotech company specializing in T cell-based immunotherapy, with NT-I7, a long-acting T cell booster, as its core pipeline. The company is developing treatments for Acute Radiation Syndrome (ARS) and CAR-T combination therapies, while also holding an exclusive North American license for Endari®, an FDA-approved sickle cell disease treatment, to drive commercialization.

Number of Employees

40people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

-64.24Industry Average -32.093.5Point

2.0x industry avg (excellent)

Debt Ratio

3.63Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.6% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -62.4% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 1Average Sentiment Score 71.2

Positive
네오이뮨텍, 이뮤노코어와 공동연구 결과 ASCO 2026 포스터 발표
네오이뮨텍과 이뮤노코어의 공동 연구로 T세포 기능 유지 가능성 확인, 면역항암 분야에서의 혁신적 진전 기대.
Positive
김태경 네오이뮨텍 신임대표 자사주 매입
대표의 자사주 매입으로 기업 신뢰도 상승 및 주주 가치 증대 기대.
Negative
네오이뮨텍, 주식병합으로 15일부터 매매거래 정지
네오이뮨텍의 주식병합으로 인한 매매거래 정지로 인해 투자자들의 불안감이 증가하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 501Won52-week high 1,27052-week low 384

1-month return6.0Point

1m +24.94% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-06-09
Neutral주식등의대량보유상황보고서(일반)2026-06-05
Neutral[기재정정]코스닥시장상장외국법인외부감사인선임ㆍ해임신고서2026-06-05
Neutral분기보고서 (2026.03)2026-05-15
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-14